A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects with Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
Price : $35 *
At a glance
- Drugs Veliparib (Primary)
- Indications Advanced breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 19 Jul 2017 Status changed from active, no longer recruiting to completed.
- 21 Apr 2017 Planned End Date changed from 1 Mar 2017 to 3 May 2017.
- 21 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 3 May 2017.